Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520972/
https://ncbi.nlm.nih.gov/pubmed/28523596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3315-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia